ADHD attention turns to drugs that are easier to swallow
This article was originally published in Scrip
Executive Summary
With both generic and newer drugs prevalent on the attention deficit hyperactivity disorder (ADHD) market, some of the focus has shifted to newer products catering to patients experiencing difficulties swallowing pills. The latest to embark into this space is Neos Therapeutics, which said the US FDA has accepted for review its NDA for NT0202 an extended release orally disintegrating tablet (ODT) formulation of amphetamine polistirex for the treatment of ADHD.